• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-CDKN2A antibody :: Mouse p16INK4a/CDKN2 Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS175053
Unit / Price
Scan QR to view Datasheet
  0.1 mg  /  $315 +1 FREE 8GB USB
anti-CDKN2A antibody
Product Name

p16INK4a/CDKN2 (CDKN2A), Monoclonal Antibody

Popular Item
Full Product Name

Anti-p16INK4a/CDKN2 antibody (monoclonal)

Product Synonym Names
Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase inhibitor 2A; ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A; CDK4 INHIBITOR; cyclin-dependent kinase inhibitor 2A(melanoma, p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1; Collaborator of ARF
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
gene 606719
3D Structure
ModBase 3D Structure for P42771
Clone Number
Species Reactivity
No cross reactivity with other proteins.
Mouse ascites fluid, 1.2% sodium acetate, 2mg BSA, with 0.01mg NaN3 as preservative.
Recombinant human p16 protein.
1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100ug/ml.
Preparation and Storage
At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for a longer time.

Avoid repeated freezing and thawing.
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of anti-CDKN2A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-CDKN2A antibody
Description: Mouse IgG monoclonal antibody for p16INK4a/CDKN2, cyclin-dependent kinase inhibitor 2A (CDKN2A) detection. Tested with WB, IHC-F, ICC in Human. No cross reactivity with other proteins. Uniprot ID: P42771
Background: p16(INK4A), also known as cyclin-dependent kinase inhibitor 2A(CDKN2A), or multiple tumor suppressor 1(MTS1). The p16 gene(CDKN2A) was mapped to 9p21. The p16 gene encodes a negative regulator of the cell cycle. CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas. Germ-line mutations in the CDKN2A tumor-suppressor gene have been linked to the development of melanoma in some families with inherited melanoma.
Applications Tested/Suitable for anti-CDKN2A antibody
Western Blot (WB), Immunohistochemistry (IHC) Formalin, Immunocytochemistry (ICC)
Application Notes for anti-CDKN2A antibody
Western Blot

Concentration: 0.5-1 ug/mL
Tested Species: Human

Imunohistochemistry (Frozen Section)

Concentration: 1-2 ug/mL
Tested Species: Human


Concentration: 1 ug/mL
Tested Species: Human

Other applications have not been tested.
Optimal dilutions should be determined by end
NCBI/Uniprot data below describe general gene information for CDKN2A. It may not necessarily be applicable to this product.
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
NCBI Official Synonym Full Names
cyclin-dependent kinase inhibitor 2A
NCBI Official Symbol
CDKN2A  [Similar Products]
NCBI Official Synonym Symbols
ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
  [Similar Products]
NCBI Protein Information
cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; multiple tumor suppressor 1; cell cycle negative regulator beta; CDKN2A {ECO:0000312|EMBL:AAM77919.1}; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
UniProt Protein Name
Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
UniProt Synonym Protein Names
Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A
Protein Family
UniProt Gene Name
CDKN2A  [Similar Products]
UniProt Synonym Gene Names
CDKN2; MTS1; CDK4I; MTS-1; p16-INK4; p16INK4A  [Similar Products]
UniProt Entry Name
NCBI Summary for CDKN2A
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
UniProt Comments for CDKN2A
p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Nucleolus; Tumor suppressor; Cell cycle regulation

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; cytosol; nucleus

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; protein kinase binding; transcription factor binding

Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of immature T cell proliferation in the thymus; caspase activation; protein destabilization; transcription, DNA-dependent; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; mitotic cell cycle; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.